Core Viewpoint - Recently, the company announced a supplemental agreement with Hangzhou Xianweida Biotechnology Co., Ltd. regarding the technology transfer of GLP-1 related drugs, which aims to clarify the revenue sharing arrangements for future earnings from the collaboration [1] Revenue Sharing Arrangement - The agreement specifies that the future variable revenue sharing ratio for the targeted products will be: 5% if a recombinant expression process is used; 2.5% if a chemical synthesis process is employed [1]